Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC)
Early Phase 1
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: Fu Zheng Jie Du Hua Yu therapy
- Registration Number
- NCT05152498
- Lead Sponsor
- Beijing Ditan Hospital
- Brief Summary
The treatment of HBV related hepatocellular carcinoma has always been a worldwide problem. The aim of this study is to alleviate the progression of hepatitis B related hepatocellular carcinoma by the Chinese medicine "Fu Zheng Jie Du Hua Yu" Principle.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 142
Inclusion Criteria
- Meet the criteria of hepatocellular carcinoma
- Ages Eligible for Study: ≤75 years old;
- Informed consent from the patient.
Exclusion Criteria
- Serious problem of heart, lung, or kidney with severe dysfunction;
- Pregnant or child breast feeding women;
- Mental or cognitive disorders;
- Participating in other drug trials;
- Who are allergic to the study drug
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Routine medical care Fu Zheng Jie Du Hua Yu therapy - Fu Zheng Jie Du Hua Yu therapy Fu Zheng Jie Du Hua Yu therapy -
- Primary Outcome Measures
Name Time Method Time to Progression 1 year
- Secondary Outcome Measures
Name Time Method overall survival 1 year progression-free survival 1 year complete response 1 year
Trial Locations
- Locations (1)
Zhiyun Yang
🇨🇳Beijing, Beijing, China